10-Q: iSpecimen Reports Q3 2025 Loss Amid Revenue Drop, Capital Raises

iSpecimen Inc. reported a significant 76% revenue decrease for the nine months ended September 30, 2025, alongside a reduced net loss and successful capital raises, but faces ongoing legal challenges and a 'going concern' warning.

Summary

• Revenue for the nine months ended September 30, 2025, decreased by 76% to $1,877,237, down from $7,815,608 in the same period of 2024.
• Net loss for the nine months ended September 30, 2025, improved by 15% to $(5,486,287) compared to $(6,450,994) in the prior year.
• The company raised approximately $3.49 million net from an underwritten public offering and $1.65 million net from a private placement in July and August 2025, respectively.
• Cash and cash equivalents increased by 48% to $2,782,758 as of September 30, 2025, from $1,878,408 at December 31, 2024.
• Management identified a material weakness in internal control over financial reporting related to sales tax documentation, calculation, collection, and remittance, and disclosure controls were deemed not effective.
• The company continues to face "substantial doubt" about its ability to continue as a going concern for the next year.
• Significant cost reductions were achieved, with monthly compensation costs down 76% and technology costs down 69% for the nine months ended September 30, 2025, compared to the same period in 2024.
• The company is involved in several legal disputes, including claims from Azenta US, Inc. ($651,262), EGSEllenoff Grossman & Schole LLP ($425,684), and Focus Technology Solutions, LLC ($489,572), the latter of which caused a platform shutdown.

Sentiment

Score: 3

Explanation: The company faces substantial doubt about its ability to continue as a going concern, driven by a massive 76% revenue decline and recurring losses. While cost reductions and recent capital raises provide some liquidity, the ineffectiveness of internal controls and ongoing legal battles, including a platform shutdown, highlight severe operational and governance weaknesses. The positive cash flow from financing is primarily due to dilutive equity raises.

Positives

• Net loss decreased by 15% for the nine months ended September 30, 2025, to $(5,486,287) from $(6,450,994) in the prior year.
• Net cash used in operating activities decreased by 29% to $(3,323,685) for the nine months ended September 30, 2025, from $(4,691,032) in the prior year.
• Successful capital raises in Q3 2025 generated approximately $5.14 million in net proceeds.
• Cash and cash equivalents increased by 48% to $2,782,758 as of September 30, 2025, compared to $1,878,408 at December 31, 2024.
• Working capital deficit improved by $85,985, from $(2,182,488) at December 31, 2024, to $(2,096,503) at September 30, 2025.
• Significant cost reductions achieved: monthly compensation costs down 76% and technology costs down 69% for the nine months ended September 30, 2025, compared to the same period in 2024.
• Sales and marketing expenses decreased by 27% to $1,746,424 for the nine months ended September 30, 2025.
• Supply development expenses decreased by 49% to $215,144 for the nine months ended September 30, 2025.
• Fulfillment costs decreased by 46% to $695,772 for the nine months ended September 30, 2025.
• General and administrative expenses decreased by 37% to $2,571,103 for the nine months ended September 30, 2025.
• Sales tax liability and related interest/penalties significantly reduced from $524,000 at December 31, 2024, to $340,000 at September 30, 2025.
• Regained Nasdaq compliance on October 1, 2024, following a 1-for-20 reverse stock split.
• Settled a legal claim with former CIO Benjamin Bielak for $215,000, significantly less than the original $586,800 claim.

Negatives

• Revenue decreased by 76% to $1,877,237 for the nine months ended September 30, 2025, compared to $7,815,608 in the prior year.
• Specimen count decreased by 74% to 5,122 for the nine months ended September 30, 2025, from 19,620 in the prior year.
• Average selling price decreased by 8% to $366 for the nine months ended September 30, 2025.
• Average cost per specimen increased by 26% for the nine months ended September 30, 2025.
• The company has recognized recurring losses since inception and has an accumulated deficit of $77,348,904 as of September 30, 2025.
• Management concluded that disclosure controls and procedures were not effective as of September 30, 2025, due to a material weakness in sales tax controls.
• The company faces "substantial doubt" about its ability to continue as a going concern.
• Ongoing legal disputes with Azenta US, Inc. ($651,262 claim), EGSEllenoff Grossman & Schole LLP ($425,684 claim), and Focus Technology Solutions, LLC ($489,572 claim, plus platform disruption and court-ordered pre-judgment security).
• Total assets decreased by 4% to $8,997,557 as of September 30, 2025.
• Total stockholders equity decreased by 7% to $3,072,711 as of September 30, 2025.
• The Russian-Ukrainian war continues to impact supply chain logistics and economic feasibility for suppliers in those regions.

Risks

• Substantial doubt regarding the company's ability to continue as a going concern for a period of one year from the date of the financial statements.
• Inability to successfully obtain additional working capital or attain profitable operations.
• Failure to increase revenues or contain operating expenses could negatively impact business, results of operations, and financial condition.
• Scaling down the business plan further if insufficient revenue is generated for adequate working capital.
• Material weakness in internal control over financial reporting related to sales tax documentation, calculation, collection, reporting, and remittance.
• Ongoing legal proceedings, including claims from Azenta US, Inc. ($651,262), EGSEllenoff Grossman & Schole LLP ($425,684), and Focus Technology Solutions, LLC ($489,572), which could divert management time and attention and incur financial costs.
• Uncertainty regarding the outcome of the Focus Technology Solutions, LLC litigation, including potential pre-judgment security requirements and counterclaims.
• Impact of global economic conditions, including inflation, on customer spending for research and employee salaries.
• Continued negative impact from the Russian-Ukrainian war on supply network accessibility, logistics, transportation, and margins.
• Reliance on a limited number of key suppliers after the "supplier network refresh project."
• Potential for additional material weaknesses in internal control over financial reporting to arise in the future.
• Availability of Net Operating Loss (NOL) carryforwards may be subject to annual limitations under Section 382 of the Internal Revenue Code due to changes in ownership provisions.

Future Outlook

The company plans to improve sales and revenues while significantly reducing and managing expenditures. It aims to leverage its "supplier network refresh project" and strategic business intelligence to support a sales overhaul, including a new account-based sales approach and an outbound sales team. The goal is to increase the speed of opportunities through the sales funnel and improve conversion ratios to grow revenue. However, the company acknowledges that certain elements of its operating plan are not within its control and cannot assess their probability of success, leading to substantial doubt about its ability to continue as a going concern.

Management Comments

• "Our mission is to accelerate life sciences research and development via a single global marketplace platform, the iSpecimen Marketplace, which connects researchers to subjects, specimens, and associated data."
• "We believe that our business will continue to be resilient through a continued industry-wide economic slowdown in life science research, and that we will continue to work on improving our liquidity to address our financial obligations and alleviate possible adverse effects on our business, financial condition, results of operations or prospects."
• "Executive management of the Company continues to review the Company's structure, processes, and resources to evaluate and identify areas for improvement, and has been focused on creating and ensuring a runway for growth and scale for the business."
• "We are committed to developing our technology, we are investing at a significantly lower level in 2025 when compared to 2024 and prior years, while we focus on growing our revenues through key market opportunities and assessing our capital raise prospects."
• "We now have a key supplier program whereby we proactively engage with the suppliers to promote our business through marketing campaigns and supplier organizations offerings."
• "We will continue adjusting the shape of the business toward our core competencies and the market. We can better use key insights from our sales data to understand market needs to assess areas where we lose deals today, through multiple lenses, in order to adjust our supplier network and marketing efforts accordingly."
• "Management believes that the unaudited condensed financial statements included in this Quarterly Report fairly present, in all material respects, our financial position, results of operations and cash flows as of and for the periods presented, in conformity with GAAP."

Industry Context

The company operates in the life sciences research and development sector, specifically in biospecimen procurement. It acknowledges that its financial performance is subject to global economic conditions and discretionary spending by customer research organizations. The industry is experiencing an economic slowdown, which the company believes its business can be resilient through. The company's strategy of streamlining operations, focusing on high-value suppliers, and implementing a "next day quote" system aims to gain efficiency and market share in a competitive environment. The digital transformation of its platform is a key investment to modernize infrastructure and improve engagement, aligning with broader trends in digitalizing scientific research workflows.

Management Changes

Corporate Governance

Legal Proceedings

• Benjamin Bielak (former CIO) arbitration: Claimed $586,800 for bonus and severance. Settled for $215,000 on January 30, 2025.
• Azenta US, Inc. claim: Initiated around January 15, 2025, for $651,262 for breach of contract and unjust enrichment. Company intends to vigorously defend. Currently in discovery phase.
• EGSEllenoff Grossman & Schole LLP claim: Initiated around November 14, 2024, for $425,684 for breach of contract and quantum meruit. Company intends to vigorously defend. Settlement discussions ongoing.
• Focus Technology Solutions, LLC complaint: Filed December 9, 2024, for $489,572 for non-payment of IT services. Focus disabled iSpecimen Marketplace (Jan 25 Feb 12, 2025). Settlement agreement for $500,000 in 9 installments. Company made initial $50,000 payment, then withheld due to Focus's failure to fully restore platform. Focus seeking to amend complaint and requested $450,000 pre-judgment security. Court partially granted, requiring company to deposit 15% of revenue up to $420,000 into a dedicated bank account by April 20, 2025. Company opposing and intends to assert counterclaims.

Stakeholder Impact

• Shareholders: Significant dilution from recent equity offerings, "going concern" warning, and material weakness in internal controls could negatively impact share value. Reduced net loss and increased cash from financing might offer some short-term stability.
• Employees: Workforce reductions have occurred, impacting compensation costs. Ongoing operational streamlining efforts may lead to further changes.
• Customers: Platform shutdown due to legal dispute with Focus Technology Solutions, LLC caused service disruption. Efforts to improve sales cycle and "next day quotes" aim to enhance customer experience.
• Suppliers: "Supplier network refresh project" resulted in termination of 180 agreements, focusing on fewer key suppliers. Russian-Ukrainian war continues to pose challenges for some suppliers.
• Creditors: The company's "going concern" warning and negative working capital indicate elevated risk. Recent capital raises provide some liquidity to address financial obligations.

Next Steps

• Continue efforts to generate additional revenues.
• Defer certain projects and capital expenditures.
• Eliminate certain future operating expenses.
• Implement a remediation plan to improve internal control over financial reporting, specifically for sales tax processes.
• Continue pursuing nonresponsive customers for sales tax exemption letters or proof of use tax payment.
• Continue VDA filings and registrations for sales and use taxes in certain states, and remit past due and current periodic sales and use taxes.
• Train appropriate personnel on enhanced sales tax policies, procedures, and controls.
• Vigorously defend against legal claims from Azenta US, Inc. and EGSEllenoff Grossman & Schole LLP.
• Oppose Focus Technology Solutions, LLC's efforts to enforce the settlement agreement and assert counterclaims for consequential damages.
• Continue to seek relief from the court-ordered pre-judgment security related to Focus Technology Solutions, LLC.
• Re-organize the commercial end of the business with a new account-based sales approach and an outbound sales team.
• Integrate marketing and sales more closely to improve efficiencies.
• Leverage strategic business intelligence to adjust supplier network and marketing efforts, and expand into winning market niches or disease states.

Key Dates

Recommendation

The company faces "substantial doubt" about its ability to continue as a going concern, a critical red flag for investors. Revenue plummeted by 76% year-over-year, indicating severe business contraction. While net loss decreased, this is overshadowed by the revenue collapse and the fact that the company still operates at a significant loss with a large accumulated deficit. The disclosure of "not effective" internal controls due to a material weakness in sales tax processes points to fundamental governance and operational deficiencies. Furthermore, multiple ongoing legal disputes, including one that led to a platform shutdown and a court-ordered pre-judgment security, introduce significant operational and financial uncertainty. Despite recent capital raises, these are dilutive and merely provide a temporary lifeline without addressing the core profitability and going concern issues. The overall picture suggests a highly distressed company with significant risks to capital.

Keywords

Biospecimen Marketplace, Life Science Research, SEC Filing, 10-Q Report, Financial Results, Going Concern, Capital Raise, Biotechnology, Medical Research, Nasdaq Compliance, Internal Controls, Legal Proceedings, Cost Reduction, Digital Transformation, Equity Financing